Investing.com – U.S. stocks were mixed after the close on Wednesday, as gains in the Technology, Oil & Gas and Financials sectors led shares higher while losses in the Basic...
Investing.com – U.S. stocks were lower after the close on Wednesday, as losses in the Basic Materials, Oil & Gas and Financials sectors led shares lower. At the close in NYSE, the...
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that the FDA has granted the company Investigational New Drug status for its gene therapy candidate, BMN 307 in patients with...
Investors everywhere may be unfamiliar with the complex science behind modern gene editing techniques, but they’ll likely want to brush up on this tech now that NASDAQ:FIXX,...
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
|Average||12.1375 (+722.88% Upside)|
|No. of Analysts||8|